Biogen

This study is testing two oral medications, diroximel fumarate (DRF) and dimethyl fumarate (DMF), in children and teenagers with relapsing forms of multiple sclerosis (MS). The main goals are to see how safe these drugs are for young people and to compare how well they control MS…

This study is testing a new drug called salanersen (BIIB115) for people aged 15-60 with spinal muscular atrophy (SMA). The goal is to see if it can improve muscle movement and function. It will include people who have never had SMA treatment and those who are switching from the d…

This study is testing whether adding a drug called salanersen can improve outcomes for babies with spinal muscular atrophy (SMA) who have already received a one-time gene therapy. Researchers want to see if this follow-up treatment is safe and if it helps babies gain more movemen…

This study continues monitoring a drug called felzartamab in kidney transplant patients whose bodies are attacking their new kidneys. It follows 120 people from an earlier trial for up to four more years to check long-term safety and effects. Researchers will track kidney health …

This study aims to monitor the long-term safety of tofersen (Qalsody), a prescription drug for a specific genetic form of ALS. Researchers will follow about 125 people with SOD1-ALS for at least 7 years, collecting health data from their regular clinic visits. The main goal is to…